LAB (BUY, PT\$24.00)

Flash: Lab Day. Strategies focused on core brands and productivity

- Genomma's new phase is just about to begin and will help detonate greater value by focusing on core brands, divesting non-strategic assets, and supporting productivity
- Despite a weak 4Q22, outlook is solid, and investments will begin to generate benefits. Based on the above, we reaffirm the company in our Top-Picks

Higher sales and margins are expected for the next few years, which will be supported on plant efficiencies and core brands development. Investor day remained largely in line with expectations, with sales growth close to our forecasts, but with an accelerated increase in profitability for the coming years. Among the highlights, LAB maintains the following targets from 2024 to 2025: (1) net sales exceeding MXN 20 billion (vs MXN 16.86 million in 2022 and vs MXN 18.26 million in 2023e) and (2) an EBITDA margin for the period between 24% and 25% (vs 20.6% in 2022 and vs 21.3% in 2023e). In this sense, expansion plan is based on 4 pillars: (1) integrated work system for manufacturing, where they plan to have zero waste and 100% labor utilization; (2) formats expansion, mainly focused on semi-solid products; (3) accelerate the transfer of external maquiladoras to internal manufacturing, and (4) dimension expansion, supported by innovation processes and greater competitiveness in exports. In addition, the company identifies five important catalysts on which it will be focusing its efforts: driving sales growth, improving margins by focusing on cost reduction, asset efficiencies, organizational optimization, and solid fundamentals.

Updated outlook for 2023. LAB established a double-digit growth expectation for all markets (including Mexico) in local currency, while on a consolidated basis, the company forecasts a mid-single-digit growth in Mexican pesos (8.3%e y/y), which would depend on the Mexican peso performance. Meanwhile, for EBITDA (12.2%e y/y), an expansion guide was established in which it should increase throughout the current year but accelerating mostly starting next year.

(1) driving brand revenues in the medium term. The company maintains a clear strategy to support sales volume of its main products, with the aim of increasing its market share from the current level: Personal care creams (8% to 10%), Analgesics (5% to 7%), Tío Nacho (3% to 5%), and Suerox (2% to 6%). To achieve these goals, three major tactical variables are considered: (1) consumer communication, representing the information channels available; (2) geographic positioning, i.e., leveraging brands presence in all regions; and (3) information processing to optimize business decisions. Considering that the plan contemplates focusing efforts on core brands, Lab could be carrying out potential divestitures or spin-offs to channel growth efforts more efficiently through

March 9, 2023

www.banorte.com @analisis_fundam


Carlos Hernández Garcia Senior Strategist, Equity carlos.hernandez.garcia@banorte.com

Paola Soto Leal Strategist, Equity paola.soto.leal@banorte.com

Marissa Garza Ostos Director of Equity Strategy marissa.garza@banorte.com

BUY	
Current Price	\$15.61
PT	\$24.00
Dividend	\$0.76
Dividend Yield (%)e	4.9%
Upside Potential	58.6%
Max – Min LTM (\$)	22.96-12.73
Market Cap (US\$m)	910.2
Shares Outstanding (m)	1,048.0
Float	71.0%
Daily Turnover (\$ m)	57.8
Valuation metrics LTM	
FV/EBITDA	6.0x
P/E	11.3x
MSCI ESG Rating*	N.A.

Relative performance to MEXBOL LTM



This document is provided for the reader's convenience only. The translation from the original Spanish version was made by Banorte's staff. Discrepancies may possibly arise between the original document in Spanish and its English translation. For this reason, the original research paper in Spanish is the only official document. The Spanish version was released before the English translation. The original document entitled "Lab Day. Estrategias enfocadas en marcas esenciales y en productividad" was released on March 9th, 2023.

Document for distribution among public

innovation, resources, and production. Based on the above, revenues are expected to contribute an additional MXN 10 billion between 2024 and 2025.

(2) Operating efficiencies targeted over the next 3 years. Increased productivity remains one of the main lines of action, where a benefit of MXN 1.8 billion is expected from the implementation of the following measures: (1) MXN 600 million derived from Toluca's plant; (2) MXN 100 million from the consolidation of vertical integration; (3) MXN 300 million obtained from scale negotiations and reengineering, both in product formulas and packaging; (4) administration expenses, reflecting administrative savings; and (5) MXN 400 million associated with a better product mix and communication platforms.

Toluca's plant as an important catalyst for growth and profitability. San Cayetano manufacturing currently produces 5% of all products, which has as an initial goal reaching 10% by 2023, but to expand its share to 30% in the medium term and end up at target levels of 60%. Considering the above, this would boost the company's vertical integration and further limit the risks caused by third-party maquila, as well as triggering the expected value for sales and profitability. Therefore, the factory is one of the most relevant expansion enablers for the next few years. It is worth mentioning that COFEPRIS approval is still pending for the oral liquids, topical liquids, and coated tablets lines. Once the operating licenses for these processes are granted, the company will begin the process of obtaining its Good Manufacturing Practices (GMP) certificate for Mexico. Subsequently, the company will seek such certification for export markets. In this context, the company expects to have most of its lines operational during this year, favoring expansion.

Despite the short-term risks, we believe the company's strategies are positive. We believe that the various measures aimed at increasing brands' market share, coupled with the full release of permits, would trigger higher value. Among the risks we are contemplating is the continued strength of the Mexican peso against most currencies, as well as a delay in obtaining the necessary certificates to operate all production lines. However, even with our conservative approach with an EBITDA margin advance of 0.75pp that we forecast in our Price Target update; the action plan is favorably positioned to face the challenges of the environment with a long-term view. We reiterate our BUY recommendation.



Certification of Analysts.

We, Alejandro Padilla Santana, Juan Carlos Alderete Macal, Alejandro Cervantes Llamas, Manuel Jiménez Zaldívar, Marissa Garza Ostos, Katia Celina Goya Ostos, Francisco José Flores Serrano, José Luis García Casales, Víctor Hugo Cortes Castro, José Itzamna Espitia Hernández, Carlos Hernández García, Leslie Thalía Orozco Vélez, Hugo Armando Gómez Solís, Yazmín Selene Pérez Enríquez, Cintia Gisela Nava Roa, Miguel Alejandro Calvo Domínguez, Daniela Olea Suárez, José De Jesús Ramírez Martínez, Gerardo Daniel Valle Trujillo, Luis Leopoldo López Salinas, Isaías Rodríguez Sobrino, Paola Soto Leal, Daniel Sebastia Sosa Aguilar and Andrea Muñoz Sánchez, certify that the points of view expressed in this document are a faithful reflection of our personal opinion on the company (s) or firm (s) within this report, along with its affiliates and/or securities issued. Moreover, we also state that we have not received, nor receive, or will receive compensation other than that of Grupo Financiero Banorte S.A.B. of C.V for the provision of our services.

Relevant statements.

In accordance with current laws and internal procedures manuals, analysts are allowed to hold long or short positions in shares or securities issued by companies that are listed on the Mexican Stock Exchange and may be the subject of this report; nonetheless, equity analysts have to adhere to certain rules that regulate their participation in the market in order to prevent, among other things, the use of private information for their benefit and to avoid conflicts of interest. Analysts shall refrain from investing and holding transactions with securities or derivative instruments directly or through an intermediary person, with Securities subject to research reports, from 30 calendar days prior to the issuance date of the report in question, and up to 10 calendar days after its distribution date.

Compensation of Analysts.

Analysts' compensation is based on activities and services that are aimed at benefiting the investment clients of Casa de Bolsa Banorte Ixe and its subsidiaries. Such compensation is determined based on the general profitability of the Brokerage House and the Financial Group and on the individual performance of each analyst. However, investors should note that analysts do not receive direct payment or compensation for any specific transaction in investment banking or in other business areas.

Last-twelve-month activities of the business areas.

Grupo Financiero Banorte S.A.B. de C.V., through its business areas, provides services that include, among others, those corresponding to investment banking and corporate banking, to a large number of companies in Mexico and abroad. It may have provided, is providing or, in the future, will provide a service such as those mentioned to the companies or firms that are the subject of this report. Casa de Bolsa Banorte or its affiliates receive compensation from such corporations in consideration of the aforementioned services.

Over the course of the last twelve months, Grupo Financiero Banorte S.A.B. C.V., has not obtained compensation for services rendered by the investment bank or by any of its other business areas of the following companies or their subsidiaries, some of which could be analyzed within this report.

Activities of the business areas during the next three months.


Casa de Bolsa Banorte, Grupo Financiero Banorte or its subsidiaries expect to receive or intend to obtain revenue from the services provided by investment banking or any other of its business areas, by issuers or their subsidiaries, some of which could be analyzed in this report.

Securities holdings and other disclosures.

As of the end of last quarter, Grupo Financiero Banorte S.A.B. of C.V. has not held investments, directly or indirectly, in securities or derivative financial instruments, whose underlying securities are the subject of recommendations, representing 1% or more of its investment portfolio of outstanding securities or 1 % of the issuance or underlying of the securities issued. None of the members of the Board of Grupo Financiero Banorte and Casa de Bolsa Banorte, along general managers and executives of an immediately below level, have any charges in the issuers that may be analyzed in this document.

The Analysts of Grupo Financiero Banorte S.A.B. of C.V. do not maintain direct investments or through an intermediary person, in the securities or derivative instruments object of this analysis report.

Guide for investment recommendations.



Even though this document offers a general criterion of investment, we urge readers to seek advice from their own Consultants or Financial Advisors, in order to consider whether any of the values mentioned in this report are in line with their investment goals, risk and financial position.

Determination of Target Prices

For the calculation of estimated target prices for securities, analysts use a combination of methodologies generally accepted among financial analysts, including, but not limited to, multiples analysis, discounted cash flows, sum-of-the-parts or any other method that could be applicable in each specific case according to the current regulation. No guarantee can be given that the target prices calculated for the securities will be achieved by the analysts of Grupo Financiero Banorte S.A.B. C.V, since this depends on a large number of various endogenous and exogenous factors that affect the performance of the issuing company, the environment in which it performs, along with the influence of trends of the stock market, in which it is listed. Moreover, the investor must consider that the price of the securities or instruments can fluctuate against their interest and cause the partial and even total loss of the invested capital.

The information contained hereby has been obtained from sources that we consider to be reliable, but we make no representation as to its accuracy or completeness. The information, estimations and recommendations included in this document are valid as of the issue date, but are subject to modifications and changes without prior notice; Grupo Financiero Banorte S.A.B. of C.V. does not commit to communicate the changes and also to keep the content of this document updated. Grupo Financiero Banorte S.A.B. of C.V. takes no responsibility for any loss arising from the use of this report or its content. This document may not be photocopied, quoted, disclosed, used, or reproduced in whole or in part without prior written authorization from Grupo Financiero Banorte S.A.B. of C.V.

History of PT and Ratings

······································			
Stock	Date	Rating	PT
LAB	22/02/2023	BUY	\$24.00
LAB	26/10/2022	BUY	\$23.53
LAB	27/07/2022	BUY	\$25.80

MSCI ESG Rating scale	į
-----------------------	---

ı

CCC	В	BB	BBB	Α	AA	AAA
LAGG	ARD	А	VERAGE		LEA	DER

^{*}The MSCI ESG Rating is an indicator that evaluates companies in Environment, Society and Governance (ESG) metrics.



GRUPO FINANCIERO BANORTE S.A.B. de C.V.

Research and Strategy Alejandro Padilla Santana	Chief Economist and Head of Research	alejandro.padilla@banorte.com	(55) 1103 - 4043
Raquel Vázquez Godinez	Assistant	raquel.vazquez@banorte.com	(55) 1670 - 2967
Itzel Martínez Rojas	Analyst	itzel.martinez.rojas@banorte.com	(55) 1670 - 2251
Lourdes Calvo Fernández	Analyst (Edition)	lourdes.calvo@banorte.com	(55) 1103 - 4000 x 26
María Fernanda Vargas Santoyo	Analyst	maria.vargas.santoyo@banorte.com	(55) 1103 - 4000
Economic Research			
Juan Carlos Alderete Macal, CFA	Executive Director of Economic Research and Financial Markets Strategy	juan.alderete.macal@banorte.com	(55) 1103 - 4046
Francisco José Flores Serrano	Director of Economic Research, Mexico	francisco.flores.serrano@banorte.com	(55) 1670 - 2957
Katia Celina Goya Ostos	Director of Economic Research, Global	katia.goya@banorte.com	(55) 1670 - 1821
Yazmín Selene Pérez Enríquez	Senior Economist, Mexico	yazmin.perez.enriquez@banorte.com	(55) 5268 - 1694
Cintia Gisela Nava Roa	Senior Economist, Mexico	cintia.nava.roa@banorte.com	(55) 1103 - 4000
Luis Leopoldo López Salinas	Manager Global Economist	luis.lopez.salinas@banorte.com	(55) 1103 - 4000 x 27
Market Strategy			
Manuel Jiménez Zaldívar	Director of Market Strategy	manuel.jimenez@banorte.com	(55) 5268 - 1671
Fixed income and FX Strategy			
Leslie Thalía Orozco Vélez	Senior Strategist, Fixed Income and FX	leslie.orozco.velez@banorte.com	(55) 5268 - 1698
Isaías Rodríguez Sobrino	Strategist, Fixed Income, FX and Commodities	isaias.rodriguez.sobrino@banorte.com	(55) 1670 - 2144
Equity Strategy			
Marissa Garza Ostos	Director of Equity Strategy	marissa.garza@banorte.com	(55) 1670 - 1719
José Itzamna Espitia Hernández	Senior Strategist, Equity	jose.espitia@banorte.com	(55) 1670 - 2249
Carlos Hernández García	Senior Strategist, Equity	carlos.hernandez.garcia@banorte.com	(55) 1670 - 2250
Víctor Hugo Cortes Castro	Senior Strategist, Technical	victorh.cortes@banorte.com	(55) 1670 - 1800
Paola Soto Leal	Strategist, Equity	paola.soto.leal@banorte.com	(55) 1103 - 4000 x 17
Corporate Debt	Capiar Apalyat Carparata Daht	hugaa gamaz@hanarta aam	(EE) 1470 2247
Hugo Armando Gómez Solís	Senior Analyst, Corporate Debt	hugoa.gomez@banorte.com	(55) 1670 - 2247
Gerardo Daniel Valle Trujillo	Analyst, Corporate Debt	gerardo.valle.trujillo@banorte.com	(55) 1670 - 2248
Quantitative Analysis	Evocutive Director of Quantitative Analysis	alajandra convantos@hanorto.com	(55) 1670 - 2972
Alejandro Cervantes Llamas José Luis García Casales	Executive Director of Quantitative Analysis	alejandro.cervantes@banorte.com	
Daniela Olea Suárez	Director of Quantitative Analysis	jose.garcia.casales@banorte.com daniela.olea.suarez@banorte.com	(55) 8510 - 4608
	Senior Analyst, Quantitative Analysis		55) 1103 - 4000
Miguel Alejandro Calvo Domínguez José De Jesús Ramírez Martínez	Senior Analyst, Quantitative Analysis	miguel.calvo@banorte.com	(55) 1670 - 2220
	Senior Analyst, Quantitative Analysis	jose.ramirez.martinez@banorte.com	(55) 1103 - 4000
Daniel Sebastián Sosa Aguilar	Analyst, Quantitative Analysis	daniel.sosa@banorte.com	(55) 1103 - 4000
Andrea Muñoz Sánchez	Analyst, Quantitative Analysis	andrea.munoz.sanchez@banorte.com	(55) 1103 - 4000
Wholesale Banking Armando Rodal Espinosa	Head of Wholesale Banking	armando.rodal@banorte.com	(55) 1670 - 1889
Alejandro Aguilar Ceballos	Head of Asset Management	alejandro.aguilar.ceballos@banorte.com	(55) 5004 - 1282
Alejandro Eric Faesi Puente	Head of Global Markets and Institutional Sales	alejandro.faesi@banorte.com	(55) 5268 - 1640
Alejandro Eric r aesi r dente Alejandro Frigolet Vázquez Vela	Head of Sólida Banorte	alejandro.frigolet.vazquezvela@banorte.com	(55) 5268 - 1656
Arturo Monroy Ballesteros	Head of Investment Banking and Structured Finance	arturo.monroy.ballesteros@banorte.com	(55) 5004 - 5140
Carlos Alberto Arciniega Navarro	Head of Treasury Services	carlos.arciniega@banorte.com	(81) 1103 - 4091
Gerardo Zamora Nanez	Head of Transactional Banking, Leasing and Factoring	gerardo.zamora@banorte.com	(81) 8173 - 9127
		jorge.delavega@banorte.com	
Jorge de la Vega Grajales Luis Pietrini Sheridan	Head of Government Banking		(55) 5004 - 5121 (55) 5240 - 6422
	Head of Private Banking	luis.pietrini@banorte.com	(55) 5249 - 6423
Lizza Velarde Torres	Executive Director of Wholesale Banking	lizza.velarde@banorte.com	(55) 4433 - 4676
Osvaldo Brondo Menchaca	Head of Specialized Banking Services	osvaldo.brondo@banorte.com	(55) 5004 - 1423
Devil Aleterates A D		alejandro.arauzo@banorte.com	(55) 5261 - 4910
•	Head of Transactional Banking	-	
Raúl Alejandro Arauzo Romero René Gerardo Pimentel Ibarrola	Head of Corporate Banking	pimentelr@banorte.com	(55) 5004 - 1051
		-	